Acorda Therapeutics (ACOR) Misses Q3 EPS by 15c; Reiterates AMPYRA Net Sales Guidance

Acorda Therapeutics (NASDAQ: ACOR) reported Q3 EPS of ($0.04), $0.15 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $135.61 million versus the consensus estimate of $134.01 million.

The Company is reiterating 2016 AMPYRA net sales guidance of $475-$485 million.

For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance
• Lowe's slashes full-year sales outlook amid DIY spending pressure